In vivo CAR-T dominates conference attention, but the field remains preclinical

One of gene therapy's hottest ideas is still early

At this year's American Society of Gene and Cell Therapy meeting in Boston, one topic stood out strongly enough to define the mood of at least one conference dispatch: in vivo CAR-T. Endpoints News described the approach as being "everywhere" at ASGCT 2026 while also making clear in the article's title and excerpt that the work remains preclinical.

That combination is the real story. In vivo CAR-T is attracting major attention, but it has not yet crossed into the stage where conference enthusiasm can be mistaken for clinical maturity. The supplied source material supports that central tension and little else, but that is enough to make the moment worth tracking.

Why this theme matters

Conference attention often functions as an early signal for where research energy, company messaging, and investor focus are moving next. When a topic becomes pervasive at a major annual meeting, it usually means the field sees strategic promise in it, even if the supporting data are still limited or early. That appears to be the case here.

The Endpoints dispatch situates the discussion in a broader moment for genetic medicine, calling the meeting a crucial one for the field. Against that backdrop, in vivo CAR-T appears to be emerging as a concept with enough momentum to dominate hallway conversation and formal updates alike. The phrase "everywhere" is notable because it implies breadth of interest, not just a handful of isolated presentations.

Still preclinical means expectations need discipline

The same source also applies a clear brake: the work is still preclinical. That matters because the gap between research visibility and clinical proof can be large in cell and gene therapy. It is common for a promising modality to generate outsized excitement before questions of safety, durability, manufacturability, and translation are resolved in humans.

By emphasizing the preclinical status directly, the source avoids overstating where the science stands. For readers and industry watchers, that is the key takeaway. This is a growing theme, not a settled breakthrough. The field may be converging on in vivo CAR-T as an important direction, but it has not yet delivered the kind of evidence that would justify treating the approach as clinically established.

A signal of what the field wants next

Even without deeper detail in the supplied text, the conference framing is revealing. Gene and cell therapy has spent years confronting hard questions about delivery, cost, complexity, and scalability. A surge of attention around in vivo CAR-T suggests researchers and developers are looking for approaches that could change those constraints. The prominence of the topic indicates that many in the field think it may offer a meaningful next step.

That does not mean the challenge is solved. Preclinical enthusiasm can point to promise, but it can also expose how much work remains before a concept proves itself in patients. In practice, the most important near-term question is not whether in vivo CAR-T is fashionable. It clearly is. The more important question is whether the science can progress from conference momentum to durable clinical evidence.

For now, ASGCT 2026 appears to have established in vivo CAR-T as one of the areas to watch most closely in genetic medicine. The excitement is real. So is the distance still left to travel.

This article is based on reporting by endpoints.news. Read the original article.